Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31288285 | 1.00 | JAK2 (0.54) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL31727280 | 0.94 | SMN1; SMN2 (0.56) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL31727301 | 0.94 | SMN1; SMN2 (0.56) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL18452966 | 0.93 | JAK2 (0.53) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL30923126 | 0.93 | JAK2 (0.53) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL3058464 | 0.93 | CCR5 (0.51) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL652803 | 0.90 | JAK2 (0.53) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL18428244 | 0.90 | JAK2 (0.52) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL8569488 | 0.88 | CCR5 (0.53) | JAK2JAK1CCR5SMN1; SMN2NPC1 | |
| SCHEMBL20320016 | 0.88 | SMN1; SMN2 (0.55) | JAK2JAK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | JAK2 25/4885JAK1 234/4885CCR5 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.